The Insulin-Only Bionic Pancreas Bridging Study

Type1 Diabetes Mellitus Clinical Trial

Official title:

The Insulin-Only Bionic Pancreas Bridging Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03565666
• Other study ID #: 2018P000853
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: July 9, 2018
• Est. completion date: November 19, 2018

Study information

• Verified date: September 2019
• Source: Massachusetts General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The iLet is a closed-loop delivery system that can be used in insulin-only, bihormonal, or glucagon-only configurations. Previous studies have utilized a phone-based bionic pancreas. The iLet consists of a touchscreen-enabled, menu-driven user interface and an onboard microprocessor that provides a comprehensive and standalone platform, which allows the iLet to operate independently of smartphones or other devices and without the need for internet support during routine operation.

This is a multicenter study of adult participants with type 1 diabetes, who will manage their diabetes with the iLet bionic pancreas compared to usual care.

Description:

This study will serve as a transitional study, bridging to larger and longer outpatient pivotal studies using the insulin-only configuration of the bionic pancreas.

The Adult RCT Period will consist of a multi-center, three-period, random-order, cross-over, feasibility study in 36 adult participants ≥ 18 years old with T1D. Insulin therapy for each participant will be administered (i) using the iLet in the insulin-only configuration and the insulin analog that they use for their usual care (either Humalog or Novolog) for 7 days, (ii) in another period using the iLet in the insulin-only configuration with faster insulin aspart (Fiasp) for 7 days (iii) in a third period using the participant's own usual care (UC) for 7 days. All three experimental periods will be followed by round-the-clock, remote, telemetric monitoring for hyperglycemia (> 300 mg/dl for ≥ 90 minutes) and hypoglycemia (< 50 mg/dl for ≥ 15 minutes). Half the subjects enrolled were expected to manage their diabetes with MDI and the other half with insulin pumps in their UC. An implantable Eversense CGM will also be placed in half the study participants for a CGM comparison.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: November 19, 2018
• Est. primary completion date: November 19, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Clinical diagnosis of type 1 diabetes for at least one year and using insulin for at least 1 year

2. Diabetes managed using an insulin pump for = 3 months or with multiple daily injections (approximately 1/2 of participants should use a pump and approximately 1/2 should use MDI)

3. Age =18 years;

• There is no upper age limit in the Adult RCT Period (instead the exclusion criteria are used to restrict the participants to those healthy enough to participate in the trial)

4. HbA1c level <11.0%

• A point of care or local lab measurement is used to assess eligibility for screening.

5. At least 3 SMBG meter tests daily on average or use of a CGM and 2 or more SMBG meter tests daily on average by history

6. For females, not currently known to be pregnant

• If female, sexually active, and at risk for pregnancy, must agree to use a highly effective form of contraception to prevent pregnancy while a participant in the study. A negative urine pregnancy test will be required for all women who are post-menarche and pre-menopause who are not surgically sterile. Participants who become pregnant will be discontinued from the study.

7. An understanding of and willingness to follow the protocol and sign the informed consent and assent where applicable

Exclusion Criteria:

-The presence of any of the following is an exclusion for the study:

1. Unable to provide informed consent (e.g. impaired cognition or judgment)

2. Unable to safely comply with study procedures and reporting requirements (e.g. impairment of vision or dexterity that prevents safe operation of the BP, impaired memory)

3. Unable to speak and read English

4. Currently using for the first time a real-time CGM for < 1 month (Individuals who have been using CGM for 1 or more months are eligible)

5. Current use of non-FDA approved closed-loop or hybrid closed-loop insulin delivery system

6. Current use of insulin glulisine (Apidra) as part of usual diabetes home regimen

7. Current off-label use of faster-acting insulin aspart (Fiasp) in CSII therapy as part of usual diabetes home regimen

8. Current participation in another diabetes-related clinical trial that, in the judgment of the principal investigator, will compromise the results of this study or the safety of the participant

9. Pregnant (positive urine HCG), breast feeding, plan to become pregnant in the next 12 months, or sexually active and at risk for pregnancy without use of contraception

10. Current alcohol abuse (intake averaging >4 drinks daily in last 30 days) or other substance abuse (use within the last 3 months of controlled substances other than marijuana without a prescription)

11. Unwilling or unable or to avoid use of drugs that may dull the sensorium, reduce sensitivity to symptoms of hypoglycemia, or hinder decision making during the period of participation in the study (use of benzodiazepines or narcotics, even if by prescription, may be excluded according to the judgment of the principal investigator)

12. Stage 4 renal failure (eGFR <30) or Stage 5 renal failure on dialysis (hemodialysis or peritoneal dialysis)

13. History of cystic fibrosis, pancreatitis, or other pancreatic disease, including pancreatic tumor or insulinoma, or history of complete pancreatectomy

14. Coronary artery disease that is not stable with medical management, including unstable angina, angina that prevents moderate exercise (e.g. exercise of intensity up to 6 METS) despite medical management, or within the last 12 months before screening a history of myocardial infarction, percutaneous coronary intervention, enzymatic lysis of a presumed coronary occlusion, or coronary artery bypass grafting

15. Abnormal EKG consistent with increased risk of malignant arrhythmia including, but not limited to, evidence of active ischemia, proximal LAD critical stenosis (Wellen's sign), or prolonged QT interval (> 440 ms). Other EKG findings, including stable Q waves, are not grounds for exclusion as long as the participant is not excluded according to other criteria. A reassuring evaluation by a cardiologist after an abnormal EKG finding may allow participation.

• EKG is only required for participants =50 years old or with diabetes duration =20 years

16. For participants < 50 years of age and < 20 years since diagnosis: History of prolonged QT interval, malignant arrhythmia, or congenital heart disease

17. Congestive heart failure with New York Heart Association (NYHA) Functional Classification III or IV

18. History of TIA or stroke in the last 12 months

19. Recent history of diabetic ketoacidosis (DKA) or severe hypoglycemia in the last 6 months. Severe hypoglycemia is defined as an event that required assistance of another person due to altered consciousness, and required another person to actively administer carbohydrate, glucagon, or other resuscitative actions. This means that the participant was impaired cognitively to the point that he/she was unable to treat himself/herself, was unable to verbalize his/ her needs, was incoherent, disoriented, and/or combative, or experienced seizure or coma.

20. History of more than 1 episode of DKA requiring hospitalization in the last 2 years

21. History of more than 1 episode of severe hypoglycemia in the last year.

22. Untreated or inadequately treated mental illness (indicators would include symptoms such as psychosis, hallucinations, mania, and any psychiatric hospitalization in the last year), or treatment with anti-psychotic medications that are known to affect glucose regulation.

23. Electrically powered implants (e.g. cochlear implants, neurostimulators) that might be susceptible to RF interference

24. Unable or unwilling to completely avoid acetaminophen for duration of study

25. Established history of allergy or severe reaction to adhesive or tape that must be used in the study

26. History of eating disorder within the last 2 years, such as anorexia, bulimia, or diabulemia or omission of insulin to manipulate weight

27. Current or planned use of SGLT2 inhibitors (prior use more than 3 months prior to enrollment is acceptable; SGLT2 inhibitors should not be initiated during the trial)

28. If using GLP1, pramlintide, or metformin must be on a stable dose for 3 months prior to enrollment (these agents should not be initiated during the trial)

29. Required use of 2 or more steroid bursts in the 6 months prior to the trial

30. History of intentional, inappropriate administration of insulin leading to severe hypoglycemia requiring treatment

31. Any factors that, in the opinion of the site principal investigator or clinical protocol chair, would interfere with the safe completion of the study, including medical conditions that may require hospitalization during the trial

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1
• Type1 Diabetes Mellitus

Intervention

Device:
• iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog
iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog

Drug:
• iLet Bionic Pancreas insulin-only configuration with Fiasp
iLet Bionic Pancreas insulin-only configuration with Fiasp (faster insulin aspart)

Other:
• Usual care
Usual care

Locations

Country	Name	City	State
United States	Barbara Davis Center for Childhood Diabetes	Aurora	Colorado
United States	Nemours Children's Specialty Care	Jacksonville	Florida
United States	Stanford University	Palo Alto	California

Sponsors (1)

Lead Sponsor	Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Episodes of Severe Hypoglycemia	Pre-specified to report the total number of episodes summed across all participants	Days 3-7 for the RCT Period
Other	Episodes of Diabetic Ketoacidosis (DKA)	pre-specified to report the total number of episodes summed across all participants	Days 3-7 for the RCT Period
Other	Percentage of Time Where Glucose is Less Than 70 mg/dL		Days 3-7 for the RCT Period
Other	Percentage of Time in the Glucose Target Range of 70-180 mg/dl		Days 3-7 for the RCT Period
Other	Percentage of Time Where Glucose is Greater Than 180 mg/dL		Days 3-7 for the RCT Period
Other	Percentage of Time Where Glucose is Less Than 60 mg/dL		Days 3-7 for the RCT Period
Other	Percentage of Time Where Glucose is Greater Than 250 mg/dL		Days 3-7 for the RCT Period
Other	Percentage Time in the Glucose Target Range of 70-120mg/dL		Days 3-7 for the RCT Period
Other	Mean Absolute Relative Difference Between Dexcom G5 CGM and Contour Next One Glucose Meter	The MARD is calculated as the mean value of individual absolute relative differences (ARD). The ARD is calculated as follows: 100*(CGM-reference glucose)/reference glucose	Days 3-7 for the RCT Period
Other	Mean Absolute Relative Difference Between Senseonics Eversense CGM and Contour Next One Glucose Meter	The MARD is calculated as the mean value of individual absolute relative differences (ARD). The ARD is calculated as follows: 100*(CGM-reference glucose)/reference glucose	Days 1-7 of the Adult RCT period
Primary	Mean CGM Glucose		Days 3-7 for the RCT Period
Primary	Percentage of Time Where Glucose is Less Than 54 mg/dL		Days 3-7 for the RCT Period